August 1, 1979Clinical Pharmacology & Therapeutics

Lorcainide; II. Plasma concentration‐effect relationship

View Full Paper

Ask AI

Bookmark

Why the study?

Does lorcainide plasma concentration correlate with ECG changes and VPC suppression in patients?

Population

17 patients with ventricular premature contractions

Design

Case_series

Authors

TMThomas MeinertzInterventional Cardiology WKWolfgang KasperGoethe University Frankfurt FKFriedrich KerstingJohannes Gutenberg University Mainz

Discussion

Member takes

Implication

May support ECG-guided lorcainide dosing; leaves open prospective validation before practice change.

Structured PICO

Does lorcainide plasma concentration correlate with ECG changes and VPC suppression in patients?

Population

17 patients with ventricular premature contractions

Intervention

Lorcainide (single doses: 2 mg/kg IV, 6 mg/min IV over 30 to 40 min, 150, 300, and 500 mg orally; long-term antiarrhythmic treatment: 200 to 600 mg daily orally)

Outcome

Plasma concentration-effect relationship on frequency of ventricular premature contractions (VPCs) and ECG changes (QRS widening)surrogate

Lorcainide plasma concentrations correlate with QRS widening and VPC suppression, suggesting ECG monitoring can guide dosing regimens.

Cite This Study

Meinertz et al. (1979) studied this question.

synapsesocial.com/papers/6a907cd585f80aee81dd82d9 https://doi.org/10.1002/cpt1979262196

View Full Paper

Ask AI

Bookmark

Lorcainide; II. Plasma concentration‐effect relationship

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Lorcainide; II. Plasma concentration‐effect relationship

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider